Gene
DPYD
DPYD is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (7), Actionable biomarkers (9), Trial mentions (57), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention DPYD. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 5 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 12 of 8,738 | 0.14% | not measured | |
| 2025 | 10 of 8,875 | 0.11% | not measured | |
| 2024 | 9 of 8,597 | 0.10% | not measured | |
| 2023 | 5 of 8,275 | 0.06% | 19 of 11,460 | 0.17% |
| 2022 | 2 of 8,285 | 0.02% | 12 of 13,598 | 0.09% |
| 2021 | 4 of 8,692 | 0.05% | 12 of 15,045 | 0.08% |
| 2020 | 3 of 7,640 | 0.04% | 18 of 14,459 | 0.12% |
| 2019 | 3 of 7,300 | 0.04% | 6 of 12,159 | 0.05% |
| 2018 | 2 of 6,927 | 0.03% | 14 of 11,854 | 0.12% |
| 2017 | 3 of 6,558 | 0.05% | 12 of 11,595 | 0.10% |
Showing 10 of 37 years.
Assay-provider ledger (7)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| The Netherlands Cancer Institute | Not a company | Clinical validationAnalytical validation | 1 | May 23, 2017 |
| Agilent | Reagent supplier | Clinical validationAnalytical validation | 1 | Date unknown |
| Coriell Institute for Medical Research | Not a company | Clinical validationAnalytical validation | 1 | Date unknown |
| Illumina | Unclassified | Clinical validationAnalytical validation | 1 | Date unknown |
| KAPA Biosystems | Reagent supplier | Clinical validationAnalytical validation | 1 | Date unknown |
Showing 5 of 7 assay-provider companies.
Actionable biomarkers (9)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| DPYD splice donor variant | "Capecitabine" | reduced sensitivity | No disease recorded | Cancer Genome Interpreter |
| DPYD (I560S,D949V) | "Capecitabine" | reduced sensitivity | No disease recorded | Cancer Genome Interpreter |
| DPYD splice donor variant | Tegafur-uracil (UFT) | reduced sensitivity | No disease recorded | Cancer Genome Interpreter |
| DPYD biallelic inactivation | Flourouracil | reduced sensitivity | No disease recorded | Cancer Genome Interpreter |
| DPYD (I560S,D949V) | Tegafur-uracil (UFT) | reduced sensitivity | No disease recorded | Cancer Genome Interpreter |
Showing 5 of 9 actionable-biomarker assertions.
Trial mentions (57)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04300361 | Trial biospecimen (AACT) |
| NCT07848568 | Trial eligibility (AACT) |
| NCT06888063 | Trial eligibility (AACT) |
| NCT03127124 | Trial eligibility (AACT) |
| NCT07419464 | Trial eligibility (AACT) |
Showing 5 of 57 trial mentions.
Target-disease associations (360)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 8p23.1 microdeletion syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Abnormality of limbs | phenotype | GWAS credible sets |
| Abnormality of the integument | phenotype | GWAS credible sets |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
Showing 5 of 360 associations.
Vendor sourcing (201)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Canonical splice site: predicted to alter splicing and result in a loss or disruption of normal protein function through protein truncation. Multiple pathoge... | View ClinVar record SCV002058930.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The DPYD c.2846A>T; p.Asp949Val variant (rs67376798, ClinVar Variation ID: 88974) is reported in the literature in multiple individuals affected with recessi... | View ClinVar record SCV007330147.1 |
| Abramson Cancer Center | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Prior treatment with irinotecan 2. DPYD or UGT1A1 genotype already known 3. Severe renal or hepatic impairment (or unacceptable laboratory values), inc... | View trial NCT04736472 |
| Abramson Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Fluent in English * Currently involved in the practice or policy of GI oncology/DPYD testing/FP use/Healthcare Development OR * Prescribed a FP for GI c... | View trial NCT06559462 |
| Abramson Cancer Center | Trial sponsor | Mentioned in trial textTrial free-text mention | DPYD | View trial NCT04736472 |
Showing 5 of 201 sourcing records.
Trial-cited literature (204)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes. | Clinical pharmacology and therapeutics | 2025 | 0 |
| Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial. | JAMA network open | 2024 | 23 |
| Reconciling the biomedical data commons and the GDPR: three lessons from the EUCAN ELSI collaboratory. | European journal of human genetics : EJHG | 2024 | 11 |
| A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens. | Clinical pharmacology and therapeutics | 2024 | 8 |
| Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial. | BMC cancer | 2024 | 4 |
Showing 5 of 204 papers.
Protein variant mentions (58)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A11F | 1 | 2013 | PMID 23781135 |
| p.A12M | 1 | 2013 | PMID 23781135 |
| p.A14M | 1 | 2013 | PMID 23781135 |
| p.A15F | 1 | 2013 | PMID 23781135 |
| p.A24M | 1 | 2013 | PMID 23781135 |
Showing 5 of 58 variants.
Literature-extracted relations (73)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Epoprostenol | Chemical | associate |
Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes. | 2025 |
| "Capecitabine" | Chemical | associate |
A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens. | 2024 |
| Irinotecan | Chemical | associate |
Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation. | 2022 |
| "Capecitabine" | Chemical | associate |
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. | 2021 |
| "Capecitabine" | Chemical | associate |
Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. | 2020 |
Showing 5 of 73 relation assertions.
Organizations publishing (238)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The Netherlands Cancer Institute | Hospital | 9 | 2016 to 2024 |
| Utrecht University | Academic | 8 | 2016 to 2024 |
| University of Pennsylvania | Academic | 7 | 2015 to 2023 |
| Kanagawa Cancer Center | Hospital | 5 | 2012 to 2022 |
| Leiden University Medical Center | Hospital | 5 | 2018 to 2024 |
Showing 5 of 238 organizations.
Where DPYD appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- respiratory or thoracic disease
334 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.